Who
Gregory B. Brown
Director
Company insider
Files Form 4 as: Director, Aquestive Therapeutics; Director, Lisata Therapeutics; Director, Cambrex; Director and 10% owner, Oscient Pharmaceuticals.
In numbers
- Trades disclosed
- 45
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $541K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 18 Aug 2006
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —50,500 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —50,500 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,456 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,456 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $143K42,000 at $3.41 | filing |
| 9 Jan 2025filed 13 Jan 2025 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,789 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 9 Jan 2024filed 11 Jan 2024 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —19,480 at $0.00 | filing |
| 21 Jun 2023filed 23 Jun 2023 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 9 Jan 2023filed 11 Jan 2023 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 10 Jan 2022filed 12 Jan 2022 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —65,430 at $0.00 | filing |
| 15 Jun 2021filed 21 Jun 2021 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 11 Jan 2021filed 12 Jan 2021 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | —37,735 at $0.00 | filing |
| 16 Jun 2020filed 18 Jun 2020 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 13 Jan 2020filed 14 Jan 2020 | LSTA Lisata TherapeuticsBiotechnology | SEC FORM 4 Code A | $60K18,292 at $3.28 | filing |
| 4 Dec 2019filed 5 Dec 2019 | Cambrexoption or derivative | SEC FORM 4 Code M | —360 at $0.00 | filing |
| 4 Dec 2019filed 5 Dec 2019 | Cambrexoption or derivative | SEC FORM 4 Code M | —1,980 at $0.00 | filing |
| 4 Dec 2019filed 5 Dec 2019 | Cambrexoption or derivative | SEC FORM 4 Code M | —2,766 at $0.00 | filing |
| 4 Dec 2019filed 5 Dec 2019 | Cambrex | SEC FORM 4 Code M | $16K360 at $44.23 | filing |
News
No headline names them, or the companies they trade most, lately.